Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumors

This study demonstrates the safety and feasibility of infusing ex vivo expanded allogeneic natural killer cells, derived from healthy canine donors and activated with specific cytokines and feeder cells, for the treatment of metastatic solid tumors in dogs, showing successful cell expansion, in vitro potency against osteosarcoma, and well-tolerated administration in a phase 1 clinical trial.

The Gist

Imagine your dog's body as a bustling city under siege by a very aggressive, shape-shifting criminal gang (cancer). Usually, the city's police force (the immune system) tries to fight back, but the criminals are too strong, or the police are too tired from previous battles to do the job.

This paper is about a new strategy: bringing in a fresh, elite special forces team from outside the city to clean up the mess. Here is the story of how they did it, explained simply.

The Problem: The "Homegrown" Police Are Tired

In the past, scientists tried to train the dog's own immune cells (police) to fight the cancer. But there were two big problems:

1. The cells were worn out: Because the dog had already been treated with chemotherapy, its own cells were weak and dysfunctional.
2. It took too long: Making a custom product for one dog took weeks. By the time the "police" were ready, the cancer had often spread further.

The Solution: The "Off-the-Shelf" Special Forces

The researchers decided to try something different. Instead of using the sick dog's own cells, they went to a "donor bank" of healthy dogs. They took blood from these healthy donors, extracted their Natural Killer (NK) cells (the immune system's elite assassins), and gave them a super-charged training camp.

The Training Camp (Expansion):
Think of the NK cells as recruits. To turn them into a massive army, the scientists put them in a special gym with:

• Feeder Cells: These are like "dummy targets" (K562 cells) that the NK cells practice attacking.
• Protein Drinks (Cytokines): They gave the cells special energy drinks (IL-2, IL-21, and a new one called IL-12) to make them multiply rapidly.
• The "IL-12" Secret Sauce: They found that adding a specific protein called IL-12 was like adding a turbocharger. It didn't just make more soldiers; it made the soldiers stronger and more focused on killing cancer.

The Safety Check: Removing the "Friendly Fire" Risk

There was a catch. If you bring in cells from another dog, there's a risk they might attack the host dog's healthy tissues (like a new security guard attacking the building owner). This is called Graft-versus-Host Disease (GVHD).

To prevent this, the scientists used a "metal detector" (magnetic sorting) to remove any T-cells (the police officers who might get confused and attack the wrong people) from the training camp before sending them out. They only sent the pure NK assassins.

The Test Drive: Three Dogs, Four Missions

The team tested this on three dogs with advanced, metastatic cancer (cancer that had spread to other parts of the body).

1. Preparation: First, they gave the dogs a mild "reset" treatment (lymphodepletion) to clear out the old, tired immune cells, making room for the new elite squad.
2. The Infusion: They injected the new, super-charged NK cells into the dogs' veins.
3. The Result:
   • Safety: The dogs handled the treatment very well. There were no major disasters. One dog had a fever (a common reaction when the immune system wakes up), but it was temporary.
   • Effectiveness: Because the dogs were already very sick with widespread cancer, the study wasn't designed to see if the treatment cured them. Instead, it proved the treatment was safe and possible. It showed that you can make these cells, ship them to a dog, and inject them without hurting the patient.

The Big Picture

Think of this study as the "prototype phase" of a new vehicle.

• Before: We had a slow, broken-down car (autologous therapy) that took too long to build.
• Now: We have a prototype of a fast, "off-the-shelf" sports car (allogeneic NK cells) that can be built quickly from healthy donors.
• The Future: The researchers know the car is safe to drive, but the engine needs more power. They plan to increase the dose (put a bigger engine in) in future studies to see if it can actually stop the cancer in its tracks.

In short: This paper proves that we can take healthy cells from one dog, train them to be cancer-killing machines, and safely give them to a sick dog. It's a promising new tool in the fight against canine cancer, and potentially, human cancer too, since dogs and humans get similar types of tumors.

Technical Summary

1. Problem Statement

• Clinical Need: Companion canines suffer from spontaneous solid tumor malignancies (e.g., osteosarcoma, melanoma) that closely mirror human disease in genetics, phenotype, and tumor microenvironment. Current treatments for metastatic/refractory solid tumors have dismal outcomes (e.g., ~30% 5-year survival for metastatic osteosarcoma).
• Limitations of Autologous Therapy: Previous canine NK cell trials utilized autologous (patient-derived) cells. However, these are limited by:
  • Dysfunctional Immunity: Patient-derived cells are often exhausted or suppressed by prior chemotherapy/radiation.
  • Manufacturing Delays: Autologous processes require weeks of production, delaying care for rapidly progressing diseases.
• The Gap: While allogeneic (donor-derived) "off-the-shelf" NK cells offer a solution, there is a lack of standardized, scalable manufacturing protocols for canine NK cells, specifically regarding T-cell depletion to prevent Graft-versus-Host Disease (GVHD) and optimization of expansion cytokines to ensure potency.

2. Methodology

The study employed a multi-phase approach combining in vitro manufacturing optimization with a Phase 1 clinical pilot trial.

A. Cell Manufacturing & Optimization

• Source: Peripheral Blood Mononuclear Cells (PBMCs) were isolated from healthy canine donors.
• T-Cell Depletion Strategy: To mitigate GVHD risk, CD3+ T cells were depleted using magnetic separation (EasySep). The study compared three timing strategies:
  1. Depletion on Day 0 (start of expansion).
  2. Depletion on Day 14 (end of expansion).
  3. No depletion.
• Expansion Protocol:
  • Feeder Cells: Irradiated K562 cells transfected with 4-1BB ligand and membrane-bound human IL-15 (K562-41BBL-mbIL15).
  • Cytokines: Recombinant human IL-2 (rhIL-2) and canine IL-21 were used as the base.
  • Optimization Variable: Canine IL-12 was added to specific cultures to assess its impact on expansion and phenotype.
• Characterization: Flow cytometry was used to monitor NKp46+ (NK marker) and CD3+ (T cell marker) populations. Viability and sterility (Mycoplasma/Endotoxin) were verified against release criteria.

B. In Vitro Potency Assay

• Target: D17-mKate2 canine osteosarcoma cells (transfected with a red fluorescent reporter).
• Method: Co-culture of expanded NK cells with D17 cells at Effector:Target (E:T) ratios of 1:1, 2:1, and 5:1.
• Analysis: Incucyte live-cell imaging tracked tumor cell death (loss of red fluorescence) over 72 hours.

C. Clinical Trial (Phase 1 Pilot)

• Subjects: 3 canines with metastatic/refractory solid tumors (4 total infusions).
• Pre-conditioning: Lymphodepletion via oral cyclophosphamide (400 mg/m²) on Day -4 and IV fludarabine (10 mg/m²) on Day -3.
• Infusion: Allogeneic NK cells administered IV on Day 0 at doses ranging from $1.5 \times 10^5$ to $5.0 \times 10^5$ NK cells/kg.
• Adjuvant: Subcutaneous rhIL-2 (250,000 IU/kg) on Days 0, +7, and +14.
• Safety Monitoring: Hourly vital signs for 4 hours post-infusion; weekly veterinary oncology evaluations for 3 weeks. Adverse events graded per VCOG-CTCAE v2.

3. Key Contributions

1. Optimization of Canine NK Manufacturing: The study established that Day 0 T-cell depletion is superior to Day 14 or no depletion, resulting in higher NK cell yields and lower residual T-cell contamination.
2. Role of IL-12: This is the first reported use of IL-12 in ex vivo canine NK expansion. The addition of IL-12 consistently increased total NK cell numbers and specifically enriched a NKp46+CD8a+ double-positive population, which is associated with high cytotoxicity in canines.
3. Safety Validation: Demonstrated that allogeneic NK cells can be safely infused in canines following lymphodepletion without inducing GVHD, provided T-cell counts are strictly controlled (<$1 \times 10^5$ T cells/kg).
4. Feasibility of "Off-the-Shelf" Therapy: Proved the workflow from healthy donor blood to clinical infusion is viable within a short timeframe, bypassing the delays associated with autologous manufacturing.

4. Results

• Manufacturing:
  • Successful expansion of NK cells to ~50% NKp46+ purity after 14 days.
  • IL-12 addition led to a distinct expansion of the NKp46+CD8a+ subset.
  • Day 0 T-cell depletion consistently produced products meeting release criteria (viability $\ge$ 50%, T-cells <$1 \times 10^5$/kg).
• In Vitro Potency:
  • Incucyte assays confirmed dose-dependent cytotoxicity against D17 osteosarcoma cells.
  • High cytotoxicity was observed in expansions with low T-cell contamination, confirming that the killing was mediated by NK cells rather than contaminating T cells.
• Clinical Outcomes (3 Canines, 4 Infusions):
  • Safety: All animals tolerated lymphodepletion and infusion well. No GVHD was observed.
  • Adverse Events: One patient experienced a transient Grade 4 fever and neutropenia (Day 7), managed successfully with antibiotics. Another patient had seizures attributed to brain metastases (necropsy confirmed), not the infusion.
  • Efficacy: Due to the advanced/metastatic stage of disease at enrollment and the pilot nature of the study (low cell doses), no objective tumor responses were documented. All patients were euthanized due to progressive disease, but the study successfully established safety and feasibility.

5. Significance

• Translational Bridge: This study validates the canine model as a robust platform for testing allogeneic cellular therapies that can directly inform human clinical trials, particularly for pediatric osteosarcoma.
• Protocol Standardization: It provides a critical roadmap for manufacturing allogeneic NK cells in veterinary medicine, addressing the historical lack of consensus on canine NK cell markers (defining them as NKp46+CD3-/-CD8+/-) and optimal expansion conditions.
• Future Directions: The study sets the stage for dose-escalation trials targeting $5 \times 10^6$ NK cells/kg (currently limited to $5 \times 10^5$) and exploring combination therapies (e.g., NK cells + checkpoint inhibitors). The identification of the IL-12-induced NKp46+CD8a+ subset offers a new target for characterizing potent NK cell populations in future research.